公司資料
Prime Medicine 股價、新聞與催化劑
- 股票代碼:
- PRME
- 交易所:
- NASDAQ
- 產業:
- Biopharma
- 所在地:
- United States
股票表現
3.17 USD (+2.59%)
收盤價
最後更新: 2026年8月17日
580M USD
市值
股價為何變動
As of Aug 17, 2026, PRME closed up 2.59% at $3.17. No new same-company headline was identified in the current news window.
公司概覽
Prime Editing
Prime Medicine develops genetic medicines using Prime Editing, a technology designed to make precise DNA changes without requiring double-strand breaks. Its programs target diseases that may be addressed by correcting pathogenic variants in vivo or ex vivo.
PM577
PM577 is an in vivo Prime Editing candidate designed to correct disease-causing mutations in the liver for Wilson disease.
PM647
PM647 is an in vivo liver-directed program for alpha-1 antitrypsin deficiency and is approaching clinical development on a timeline similar to PM577.
Chronic Granulomatous Disease
PM359 is an ex vivo edited cell therapy for chronic granulomatous disease. Prime Medicine is continuing regulatory dialogue with the FDA regarding a potential BLA path.
未來催化劑
- IND and/or CTA submission for PM577 in Wilson disease in the first half of 2026.
- IND and/or CTA submission for PM647 in alpha-1 antitrypsin deficiency around mid-2026.
- Initial clinical data from PM577 and PM647 in 2027.
近期新聞
- 01
- 02
- 03
- 04
- 05
相似股票
商業成熟度、治療領域或催化劑模式相近的同業公司。